Citizens JMP raised the firm’s price target on Rapport Therapeutics (RAPP) to $80 from $77 and keeps an Outperform rating on the shares. Rapport reported Q3 results and said it continues to advance RAP-219 development, the analyst tells investors in a research note. The firm continues to believe that the results from the Phase 2a proof-of-concept study evaluating RAP-219 in focal epilepsy can be rapidly and broadly adopted in clinical practice.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RAPP:
- Rapport Therapeutics Reports Q3 2025 Financial Results
- Promising Phase II Results and Strong Financial Position Drive Buy Rating for Rapport Therapeutics
- Rapport Therapeutics reports Q3 EPS (71c), consensus (73c)
- Rapport Therapeutics’ New Study on RAP-219: A Potential Game-Changer for Epilepsy Treatment
- Rapport Therapeutics’ RAP-219 Study: A Potential Game-Changer for Bipolar I Disorder